These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8204512)
21. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417 [TBL] [Abstract][Full Text] [Related]
22. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927 [TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era. Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP Tumori; 2015; 101(1):2-7. PubMed ID: 25702654 [TBL] [Abstract][Full Text] [Related]
26. The importance of dose: lymphomas as a model of chemosensitive malignancies. Bronchud MH Eur J Cancer; 1993; 29A Suppl 5():S17-22. PubMed ID: 8260261 [TBL] [Abstract][Full Text] [Related]
27. [Treatment of aggressive non-Hodgkin's lymphomas]. López A; Palacio C Med Clin (Barc); 1998 May; 110(16):614-8. PubMed ID: 9656199 [No Abstract] [Full Text] [Related]
28. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930 [TBL] [Abstract][Full Text] [Related]
29. The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer. Demetri GD Hematol Oncol Clin North Am; 1994 Feb; 8(1):233-49. PubMed ID: 8150782 [TBL] [Abstract][Full Text] [Related]
30. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838 [TBL] [Abstract][Full Text] [Related]
31. Biotherapy in hematology: the next decade. Quesenberry PJ Rev Invest Clin; 1994 Apr; Suppl():8-15. PubMed ID: 7886315 [No Abstract] [Full Text] [Related]
32. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma. Zelenetz AD Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115 [TBL] [Abstract][Full Text] [Related]